Novartis gets FDA nod for groundbreaking flu vaccine; Kiadis raises $12.8M; MabVax garners $5M in venture cash;

 @FierceBiotech: Predicting your end: Biomarkers for mortality. News | Follow @FierceBiotech

 @JohnCFierce: Feds zero in on drug experts as insider case exposes investigator's role (more to come, I suspect). Story | Follow @JohnCFierce

 @RyanMFierce: With ex-BMSer Jeremy Levin at the helm, Teva wants to do buyouts that are smaller than the deals that made Teva big. More | Follow @RyanMFierce

> The FDA has approved Flucelvax from Novartis ($NVS), the first seasonal flu product made from animal cell technology. Story

> The blood-cancer drug developer Kiadis Pharma has raised $12.8 million in a round led by Life Sciences Partners with support from DFJ-Esprit, Alta Partners, Quest for Growth and NOM. Report

> MabVax Therapeutics has raised $5.25 million, with much of the money earmarked for a mid-stage study of an experimental cancer vaccine to prevent the recurrence of sarcoma. Story

> Algeta and Ablynx have struck a research collaboration to evaluate a novel Targeted Thorium Conjugate combining Algeta's proprietary thorium-227 alpha-pharmaceutical payload with "Nanobodies" generated using Ablynx's technology platform. Release

Pharma News

@FiercePharma: Novartis nabs FDA approval for 1st flu vaccine made without eggs. Produced at plant that got $500M in gov't aid. More (sub. req.) | Follow @FiercePharma

> New Teva CEO, new small-is-beautiful M&A strategy. Report

> Novartis fast production, cell-culture flu vaccine OK'd by FDA. Article

> Armed with EU stroke approval, Pfizer, BMS talk up Eliquis' edge over rivals. Story

> PwC sees golden era for pharmas that dump the junk, innovate. News

 @FierceMedDev: FDA faults St. Jude's manufacturing for Durata ICD leads. St. Jude disclosed the report but kept "Durata" out. More | Follow @FierceMedDev

 @MarkHFierce: Zimmer will train regulators in China in an unusual deal. Release | Follow @MarkHFierce

 @DamianFierce: Novartis' Alcon is buying the ophthalmic surgery unit of German company SensoMotoric. Story | Follow @DamianFierce

> Boston Scientific gets CE mark for expanded CRM longevity. Article

> HeartWare snags FDA approval for novel heart pump. News

Drug Deliver News

> Fujifilm joins microneedle R&D boom. Report

> Reinforced gels deliver drugs and cells. Article

> Pfizer hits ups, downs with controlled-release Lyrica. News

> Nanoparticles deliver antigen to trick the immune system in MS. Story

Biomarkers News

> Predicting your end: Biomarkers for mortality. Article

> Kidney problems tag development delays? Story

> Saliva markers diagnose gum disease. News

> DoD's $1.15M grant may lead to blood test to catch heavy drinkers. Item

Vaccine News

> J&J hits development roadblock with Crucell candidates. Article

> FDA panel concerned about safety of Dynavax's hep B vaccine. News

> Novartis nabs EU committee backing for meningitis B vaccine. Story

> GSK's Synflorix gleans positive results in infants. Report

> FDA approves Novartis flu vaccine. Item

And Finally… A*STAR scientists say they have identified the enzyme telomerase as a cause of chronic inflammation in human cancers. Release

 

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.